NasdaqGM:EYPTPharmaceuticals
Can EyePoint (EYPT) Turn DURAVYU’s Six‑Month Dosing Goal Into Lasting Competitive Advantage?
EyePoint Pharmaceuticals recently presented at the Stifel 2026 Virtual Ophthalmology Forum and reiterated that top-line Phase 3 data for its wet age-related macular degeneration (AMD) therapy DURAVYU are expected to begin reading out in August, with a second pivotal trial to follow about two months later.
Management highlighted 2026 as potentially transformative, emphasizing ambitions for DURAVYU to match a leading therapy on vision outcomes while maintaining safety and reducing treatment...